86447-11-2

Basic information

• Product Name: 1-Boc-1,2,5,6-tetrahydropyridine-3-carboxylic acid
• Synonyms: 1-[(tert-butoxy)carbonyl]-1,2,5,6-tetrahydropyridine-3-carboxylic acid;1-[(2-methylpropan-2-yl)oxycarbonyl]-3,6-dihydro-2h-pyridine-5-carboxylic Acid;1-Boc-1,2,5,6-tetrahydropyridine-3-carboxylic acid
• CAS NO: 86447-11-2
• Molecular Formula: C₁₁H₁₇NO₄
• Molecular Weight: 227.26
• Mol File: 86447-11-2.mol

Chemical Properties

• Boiling Point: 356.942°C at 760 mmHg
• Flash Point: 169.673°C
• Appearance: /
• Density: 1.207g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.519
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-Boc-1,2,5,6-tetrahydropyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-1,2,5,6-tetrahydropyridine-3-carboxylic acid(86447-11-2)
• EPA Substance Registry System: 1-Boc-1,2,5,6-tetrahydropyridine-3-carboxylic acid(86447-11-2)

Safety Data

• Hazardous Substances Data: 86447-11-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Boc-1,2,5,6-tetrahydropyridine-3-carboxylic acid is used as a building block for the synthesis of pharmaceuticals. Its unique structure and the presence of the Boc-protective group make it a versatile component in the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 1-Boc-1,2,5,6-tetrahydropyridine-3-carboxylic acid is employed as a key intermediate for the preparation of various organic compounds. Its reactivity and the ability to protect amines with the Boc group facilitate the synthesis of complex molecules with specific functional groups.
Used in Chemical Research:
1-Boc-1,2,5,6-tetrahydropyridine-3-carboxylic acid is utilized in chemical research to explore novel synthetic pathways and develop innovative methodologies for the preparation of biologically active molecules. Its unique properties and the Boc-protective group offer opportunities for the discovery of new chemical reactions and the synthesis of diverse organic compounds.

InChI:InChI=1/C11H17NO4/c1-11(2,3)16-10(15)12-6-4-5-8(7-12)9(13)14/h5H,4,6-7H2,1-3H3,(H,13,14)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 6027-92-5 guvacine hydrobromide 
• 7646-93-7 potassium hydrogensulfate 
• 126114-09-8 1-(tert-butyl) 3-ethyl 1,2,5,6-tetrahydropyridine-1,3-dicarboxylate 
• 125097-83-8 methyl 1-tert-butoxycarbonyl-1,2,5,6-tetrahydropyridine-3-carboxylate 
• 498-96-4 guvacine 
• 495-19-2 norarecoline 
• 92600-27-6 1-(1-chloroethyl) 3-methyl 5,6-dihydropyridine-1,3(2H)-dicarboxylate 
• 300-08-3 arecoline hydrobromide 
• 86447-10-1 methyl N-2,2,2-trichloroethyloxycarbonyl-1,2,5,6-tetrahydropyridine-3-carboxylate 
• 63-75-2 arecoline 
• 98977-34-5 1-tert-butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate 
• 4644-61-5 ethyl 4-piperidone-3-carboxylate hydrochloride 
• 6027-91-4 1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride 

Downstream Products

• 88495-54-9 (3S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid 
• 163438-09-3 (R)-1-Boc-nipecotic acid 
• 885693-20-9 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 915233-34-0 5-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-1,2,3,6-tetrahydro-pyridine hydrochloride 
• 915233-33-9 5-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein NA (I) and pharmaceutically acceptable salts thereof.5 Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein formula (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS

The invention provides novel imidazopyrazine derivatives having general formula (I), wherein R1 to R11 are as described herein, and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R14 are as described herein (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

NOVEL IMIDAZOPYRAZINE DERIVATIVES

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein (I) and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

Flow Photo-Nazarov Reactions of 2-Furyl Vinyl Ketones: Cyclizing a Class of Traditionally Unreactive Heteroaromatic Enones

Nazarov reactions of 2-furyl vinyl ketones and related heteroaromatic enones, to produce furan-fused cyclopentanones using a flow photochemical approach, are described. Compounds possessing this connectivity between heterocycle and ketone (2-furyl, 2-benzofuryl, 2-thiophene-yl, and 2-benzothiophene-yl) have traditionally proven difficult or impossible to cyclize with typical Br?nsted and Lewis acid mediated methods. Using mild flow photochemistry conditions and acetic acid (AcOH) or hexafluoroisopropanol (HFIP) as solvent, these compounds were found to cyclize in 45-97% yields, with typical UV exposure times of 3.4-6.8 min. In all cases, 2-furyl and 2-thiophene-yl enones cyclized, whereas 2-benzofuryl and 2-benzothiophene-yl enones exhibited divergent properties with reactivity patterns tied to the identity of the vinyl group. This report discloses the first photo-Nazarov reactions of tetrahydropyridine-substituted 2-furyl ketones, providing a direct approach to the corresponding fused heterocyclic motifs built around a central cyclopentanone. These motifs constitute the core structures of biologically active natural products, including the marine alkaloid nakadomarin A.

Discovery of potent iminoheterocycle BACE1 inhibitors

The synthesis of a series of iminoheterocycles and their structure-activity relationships (SAR) as inhibitors of the aspartyl protease BACE1 will be detailed. An effort to access the S3 subsite directly from the S1 subsite initially yielded compounds with sub-micromolar potency. A subset of compounds from this effort unexpectedly occupied a different binding site and displayed excellent BACE1 affinities. Select compounds from this subset acutely lowered Aβ40 levels upon subcutaneous and oral administration to rats.

Iridium-catalyzed enantioselective hydrogenation of unsaturated heterocyclic acids

Spiral binding: A highly enantioselective hydrogenation of unsaturated heterocyclic acids has been developed by using chiral iridium/spirophosphino oxazoline catalysts (see scheme; BArF-=tetrakis[3,5- bis(trifluoromethyl)phenyl]borate, Boc=tert-butoxycarbonyl). This reaction provided an efficient method for the preparation of optically active heterocyclic acids with excellent enantioselectivities. Copyright

Synthesis of 3-azabicyclo [4.1.0]heptane-1-carboxylic acid

A full study on the synthesis of 3-azabicyclo[4.1.0]heptane-1-carboxylic acid is described.Three different approaches were investigated in order to achieve an efficient synthesis of this unnatural aminoacid.The optimized synthetic route relies upon three key steps: (i) diazomalonate insertion on 4-phtalimido 1-butene, (ii) intramolecular cyclization and (iii) chemoselective reduction of the resulting lactam.Due to its bicyclic nature and conformational constraints, this aminoacid may be an useful building block in medicinal chemistry.

NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to new compounds which are Oxadiazole derivatives of formula (I) wherein B, P, Q,W, R1 and R2 are defined in the description. Invention compounds are useful in the prevention or treatment of central or p